Medical Oncology
Physician insights on cancer treatment protocols, immunotherapy, targeted therapies, and clinical trial updates.
Recent Discussions
What is your preferred salvage therapy for patients with follicular lymphoma who relapsed within 24 months of completing front-line chemoimmunotherapy (POD24) and will proceed to high-dose therapy with Auto-SCT?
There is no standard therapy for patients progressing within 24 months of 1L chemoimmunotherapy. If you have a well-designed clinical trial, I would do this 1st. Outside of a clinical trial, I would 1st try to biopsy a hot spot to r/o large B-cell transformation. If so, if the patient is a candidate...
What is your preferred second line regimen for follicular lymphoma that has relapsed four years out since receiving BR?
I try to move away from chemotherapy in FL in the relapse setting, especially with the available options and CAR-T in particular. I would consider lenalidomide-rituximab in second line and zanubrutinib - obinutuzumab in 3L. Obinutuzumab seems to be a better CD20 antibody for RR so lenalidomide and o...
How do you manage bruising in patients on ibrutinib?
Bruising is quite common in patients treated with ibrutinib, and it seems to be a class effect that also is seen with the 2nd generation BTK inhibitors, such as acalabrutinib. It should be mentioned when consenting patients, and reassurance generally is all that is needed because the bruising is usu...
Can acalabrutinib be used after ibrutinib failure in relapsed/refractory mantle cell lymphoma?
Acalabrutinib binds to the same pocket as ibrutinib on BTK. Theoretically, if a patient is ibrutinib resistant, acalabrutinib would not be effective. Ideally, there should have been a small trial testing this hypothesis. However, because of the theoretic concerns, nobody wants to do this trial. As w...
How do you manage bruising in patients on ibrutinib?
Bruising is quite common in patients treated with ibrutinib, and it seems to be a class effect that also is seen with the 2nd generation BTK inhibitors, such as acalabrutinib. It should be mentioned when consenting patients, and reassurance generally is all that is needed because the bruising is usu...
Can acalabrutinib be used after ibrutinib failure in relapsed/refractory mantle cell lymphoma?
Acalabrutinib binds to the same pocket as ibrutinib on BTK. Theoretically, if a patient is ibrutinib resistant, acalabrutinib would not be effective. Ideally, there should have been a small trial testing this hypothesis. However, because of the theoretic concerns, nobody wants to do this trial. As w...
What is your preferred salvage therapy for patients with follicular lymphoma who relapsed within 24 months of completing front-line chemoimmunotherapy (POD24) and will proceed to high-dose therapy with Auto-SCT?
There is no standard therapy for patients progressing within 24 months of 1L chemoimmunotherapy. If you have a well-designed clinical trial, I would do this 1st. Outside of a clinical trial, I would 1st try to biopsy a hot spot to r/o large B-cell transformation. If so, if the patient is a candidate...
What is your preferred second line regimen for follicular lymphoma that has relapsed four years out since receiving BR?
I try to move away from chemotherapy in FL in the relapse setting, especially with the available options and CAR-T in particular. I would consider lenalidomide-rituximab in second line and zanubrutinib - obinutuzumab in 3L. Obinutuzumab seems to be a better CD20 antibody for RR so lenalidomide and o...
What are the factors that convince you to not immediately treat mantle cell lymphoma and to follow a course of "active surveillance"?
A subset of patients with MCL have a significantly longer survival (often more than 7-10 years) and a more indolent disease course. Two separate groups have reported patients who did not receive up-front chemotherapy at the time of diagnosis but were instead actively monitored, the watch-a...
What is your preferred BTK inhibitor for patients with relapsed/refractory mantle cell lymphoma?
The majority of patients with relapsed/refractory MCL will respond to single agent BTKi therapy and this is my preferred treatment in patients at first relapse when a clinical trial is not available, and they have not been exposed to a BTKi (for example, on a frontline clinical trial). I often used ...